{"created":"2023-06-20T15:58:52.244863+00:00","id":16529,"links":{},"metadata":{"_buckets":{"deposit":"bb3843a8-2065-4790-b3d6-0e224e66577d"},"_deposit":{"created_by":39,"id":"16529","owners":[39],"pid":{"revision_id":0,"type":"depid","value":"16529"},"status":"published"},"_oai":{"id":"oai:redcross.repo.nii.ac.jp:00016529","sets":["98:61:579"]},"author_link":["61726","61728","61725","61727"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-03-01","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"34","bibliographicPageStart":"31","bibliographicVolumeNumber":"43","bibliographic_titles":[{"bibliographic_title":"高山赤十字病院紀要"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":" Although escitalopram (ESC) is no having dopamine (DA) transporter (DAT) inhibitory-action, having dopamine nerve (A10 nerve) stimulus operation by the ESC used basic experiment is reported. We supposed the mechanism that the DA increases and it supposed the mechanism that makes a non-organic pain disappear with ①5-HT reinforcement of the descending pain modulatory system, ②the opioid receptor activation with the descending pain modulatory system, ③negative emotion block from the amygdala and the hippocampus to the nucleus accumbens, ④5-HT1A receptor stimulation from the activation of the amygdala, ⑤DA-phasic activity activation.\n As a result ④ and ⑤ two items were an operation with a main restraint mechanism of a nonorganic-pain. ESC is different from other SSRIs, and we know that ESC make a DA increase at the VTA. We supposed amygdala that a functional depression declined by corticotropin-releasing factor (CRF) is improved with ④ and ③. After DA stimulate by A10 nerve, DA is undergone metabolic change to, and the endogenous opioid peptide (βendorphin) is made.\n","subitem_description_type":"Abstract"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"高山赤十字病院"}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0387-7027","subitem_source_identifier_type":"ISSN"}]},"item_10002_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"OHKUBO, Tsunemasa"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KAITO, Muichi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"ANDO, Toshihiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KATO, Hideaki"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-07-22"}],"displaytype":"simple","filename":"07臨床・症例検討　6大久保恒正.pdf","filesize":[{"value":"1.5 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"takayama43_007","url":"https://redcross.repo.nii.ac.jp/record/16529/files/07臨床・症例検討　6大久保恒正.pdf"},"version_id":"03f12b10-3197-497d-b098-11fd41f5aa2b"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Escitalopram","subitem_subject_scheme":"Other"},{"subitem_subject":"A10 nerve","subitem_subject_scheme":"Other"},{"subitem_subject":"non-organic pain","subitem_subject_scheme":"Other"},{"subitem_subject":"descending pain modulatory system","subitem_subject_scheme":"Other"},{"subitem_subject":"βendorphin","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"The supposition of the mechanism of escitalopram makes a dopamine nerve activity rise by inhibiting corticotropinreleasing factor to the non-organic-pain ～A SSRI application is desirable for a non-organic-pain～","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"The supposition of the mechanism of escitalopram makes a dopamine nerve activity rise by inhibiting corticotropinreleasing factor to the non-organic-pain ～A SSRI application is desirable for a non-organic-pain～"}]},"item_type_id":"10002","owner":"39","path":["579"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-07-22"},"publish_date":"2020-07-22","publish_status":"0","recid":"16529","relation_version_is_last":true,"title":["The supposition of the mechanism of escitalopram makes a dopamine nerve activity rise by inhibiting corticotropinreleasing factor to the non-organic-pain ～A SSRI application is desirable for a non-organic-pain～"],"weko_creator_id":"39","weko_shared_id":-1},"updated":"2023-06-20T18:18:23.367516+00:00"}